Data Monitoring Committees: Current issues

Clinical Trials

Volumn 15, Issue 4, 2018, Pages 321-328

  Fleming, Thomas R ^a   Ellenberg, Susan S ^b   DeMets, David L ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

confidentiality; indemnification; Independence; mediator; mission

Indexed keywords

AMFEBUTAMONE; NALTREXONE;

BLEEDING; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; CONFIDENTIALITY; DECISION MAKING; GOVERNMENT; HEART INFARCTION; HUMAN; MEDICATION COMPLIANCE; MORBIDITY; MORTALITY; NEGLIGENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL STANDARD; RISK BENEFIT ANALYSIS; CLINICAL TRIAL (TOPIC); ETHICS; PROFESSIONAL PRACTICE; STANDARDS;

CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS DATA MONITORING COMMITTEES; CONFIDENTIALITY; HUMANS; PROFESSIONAL AUTONOMY;

EID: 85045144585     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774518764855     Document Type: Conference Paper

References (20)

1. Fleming TR, DeMets DL, Roe M. Data Monitoring Committees: promoting best practices to address emerging challenges. Clin Trials 2017; 14: 115–123
2. Ellenberg SS, Fleming TR, DeMets DL., Data Monitoring Committees in clinical trials: a practical perspective. New York: Wiley, 2003
3. Office of Inspector General, U.S. Department of Health & Human Services. Data and safety monitoring boards in NIH clinical trials: meeting guidance, but facing some issues, http://oig.hhs.gov/oei/reports/oei-12-11-00070.asp (accessed 8 February 2016)
4. U.S. Food and Drug Administration. The establishment and operation of clinical trial Data Monitoring Committees for clinical trial sponsors, http://www.fda.gov/RegulatoryInformation/Guidances/ucm127069.htm (2016, accessed 8 February 2016)
5. European Medicines Agency Committee for Medicinal Products for Human Use. Guideline on Data Monitoring Committees, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003635.pdf (accessed 21 February 2018)
6. Pharmaceuticals Medical Devices Agency. Guidance on Data Monitoring Committees (PFSB/ELD notification No. 0404-1), https://www.pmda.go.jp/files/000204620.pdf (2013, accessed 16 June 2016) (in Japanese)
7. Fleming TR, Sharples K, McCall J. Maintaining confidentiality of interim data to enhance trial integrity and credibility. Clin Trials 2008; 5: 157–167
8. Anand SS, Wittes J, Yusuf S., What information should a sponsor of a randomized trial receive during its conduct? Clin Trials 2011; 8: 716–719
9. Green SJ, Fleming TR, O’Fallon JR. Policies for study monitoring and interim reporting of results. J Clin Oncol 1987; 5: 1477–1484
10. Grant AM, Altman DG, Babiker AB.; Damocles Study Group. Issues in data monitoring and interim analysis of trials. Health Technol Assess 2005; 9: 1–238, iii–iv
11. Fleming TR., Protecting the confidentiality of interim data: addressing current challenges. Clin Trials 2015; 12: 5–11
12. Nissen SE, Wolski KE, Prcela L. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA 2016; 315: 990–1004
13. Sharfstein JM, Psaty BM., Evaluation of the cardiovascular risk of naltrexone-bupropion: a study interrupted. JAMA 2016; 315: 984–986
14. Meinert CL., Masked monitoring in clinical trials—blind stupidity? N Engl J Med 1998; 338: 1381–1382
15. Echt DS, Liebson PR, Mitchell LB. Mortality and morbidity in patients receiving encainide, flecainide, or placebo—The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781–788
16. Mauri L, Kereiakes DJ, Yeh RW. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155–2166
17. Fleming TR, Hennekens CH, Pfeffer MA. Enhancing trial integrity by protecting the independence of Data Monitoring Committees in clinical trials. J Biopharm Stat 2014; 24: 968–975
18. Tereskerz PM., Data safety monitoring boards: legal and ethical considerations for research accountability. Account Res 2010; 17: 30–50
19. DeMets DL, Fleming TR, Rockhold F. Liability issues for Data Monitoring Committee members. Clin Trials 2004; 1: 525–531
20. DeMets DL, Ellenberg SE., Data Monitoring Committees—expect the unexpected. N Engl J Med 2016; 375: 1365–1371